Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| DiaMedica Therapeutics Inc.DMAC · Entity 5813 | Director | June 01, 2026 | June 03, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
DiaMedica Therapeutics Inc.
Report date June 01, 2026 · Filed June 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.84 · Expires 2036-06-01 | Direct | 40,412 |
Reported balance
After 2026-06-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-01 · Grant · Acquired 40,412 · Balance 40,412 F1: Scheduled to vest in four equal quarterly installments. |
Filing footnotes · ownership attribution and instrument terms
F1: Scheduled to vest in four equal quarterly installments.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 01, 2026 Filed Jun 3, 2026 21:26 UTC | DiaMedica Therapeutics Inc. DMAC · Entity 5813 | GrantStock Option (right to buy) · Derivative | 40,412 | $0.00 Strike: $5.84 | $0.00 |
DisclosureSEC source: 0001872863-26-000004 · form4-06032026_090620.xml · derivative · entry 1 Semba Charles Pauling · CIK 0001872863 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,412 Underlying: Voting Common Shares · 40,412 shares Expires 2036-06-01 F1 · derivative.exercise_date: Scheduled to vest in four equal quarterly installments. Read SEC document |
| January 02, 2026 Filed Jan 6, 2026 22:22 UTC | DiaMedica Therapeutics Inc. DMAC · Entity 5813 | GrantCommon Stock | 3,355 | $8.42 | $28,249.10 |
DisclosureSEC source: 0001872863-26-000002 · form4-01062026_100121.xml · nonDerivative · entry 1 Semba Charles Pauling · CIK 0001872863 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,963 F1 · shares: Shares are issuable upon settlement of restricted stock units granted under the DiaMedica Therapeutics Inc. Amended and Restated 2019 Omnibus Incentive Plan, in lieu of cash retainer fees in the aggregate amount of $28,250. The restricted stock units are scheduled to vest in four nearly equal installments on each of March 31, June 30, September 30, and December 31, 2026." Read SEC document |
| June 01, 2025 Filed Jun 3, 2025 20:18 UTC | DiaMedica Therapeutics Inc. DMAC · Entity 5813 | GrantStock Option (right to buy) · Derivative | 32,162 | $0.00 Strike: $4.11 | $0.00 |
DisclosureSEC source: 0001437749-25-019295 · rdgdoc.xml · derivative · entry 2 Semba Charles Pauling · CIK 0001872863 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,162 Underlying: Common Shares · 32,162 shares Expires 2035-05-31 F2 · derivative.exercise_date: Vests in four nearly equal quarterly installments over one year. Read SEC document |
| January 02, 2025 Filed Jan 3, 2025 21:15 UTC | DiaMedica Therapeutics Inc. DMAC · Entity 5813 | GrantVoting Common Shares, no par value per share | 5,290 | $5.34 | $28,248.60 |
DisclosureSEC source: 0001235802-25-000001 · primary_doc.xml · nonDerivative · entry 1 Semba Charles Pauling · CIK 0001872863 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,608 F1 · shares: These shares are issuable upon vesting and settlement of a restricted stock unit award granted under the DiaMedica Therapeutics Inc. Amended and Restated 2019 Omnibus Incentive Plan in lieu of cash retainer fees in the aggregate amount of $28,250. The restricted stock unit award will vest in four nearly equal installments on each of March 31, 2025, June 30, 2025, September 30, 2025 and December 31, 2025. F2 · balance_after: Includes 5,290 shares issuable on vesting of a restricted stock unit award granted under the DiaMedica Therapeutics Inc. Amended and Restated 2019 Omnibus Incentive Plan. Read SEC document |
| June 01, 2024 Filed Jun 3, 2024 20:35 UTC | DiaMedica Therapeutics Inc. DMAC · Entity 5813 | GrantStock Option (right to buy) · Derivative | 28,472 | $0.00 Strike: $2.90 | $0.00 |
DisclosureSEC source: 0001235802-24-000049 · primary_doc.xml · derivative · entry 2 Semba Charles Pauling · CIK 0001872863 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,472 Underlying: Common Shares · 28,472 shares Expires 2034-05-31 F2 · derivative.exercise_date: Vests in four nearly equal quarterly installments over one year. Read SEC document |
| January 02, 2024 Filed Jan 2, 2024 22:05 UTC | DiaMedica Therapeutics Inc. DMAC · Entity 5813 | GrantVoting Common Shares, no par value per share | 9,375 | $2.80 | $26,250.00 |
DisclosureSEC source: 0001235802-24-000005 · primary_doc.xml · nonDerivative · entry 1 Semba Charles Pauling · CIK 0001872863 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,318 F1 · shares: These shares are issuable upon vesting of a restricted stock unit award granted under the DiaMedica Therapeutics Inc. 2019 Omnibus Incentive Plan in lieu of cash retainer fees in the aggregate amount of $26,250. The restricted stock unit award will vest in four nearly equal installments on each of March 31, 2024, June 30, 2024, September 30, 2024 and December 31, 2024. F2 · balance_after: Includes 9,375 shares issuable on vesting of a restricted stock unit award granted under the DiaMedica Therapeutics Inc. 2019 Omnibus Incentive Plan. Read SEC document |
| June 23, 2023 Filed Jun 26, 2023 20:26 UTC | DiaMedica Therapeutics Inc. DMAC · Entity 5813 | PurchaseVoting Common Shares, no par value per share | 12,787 | $3.91 | $49,997.17 |
DisclosureSEC source: 0001235802-23-000071 · primary_doc.xml · nonDerivative · entry 1 Semba Charles Pauling · CIK 0001872863 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,943 F1 · balance_after: Includes 12,867 shares issuable on vesting of a restricted stock unit award granted under the DiaMedica Therapeutics Inc. 2019 Omnibus Incentive Plan. Read SEC document |
| June 01, 2023 Filed Jun 2, 2023 20:33 UTC | DiaMedica Therapeutics Inc. DMAC · Entity 5813 | GrantStock Option (right to buy) · Derivative | 16,968 | $0.00 Strike: $2.73 | $0.00 |
DisclosureSEC source: 0001235802-23-000060 · primary_doc.xml · derivative · entry 2 Semba Charles Pauling · CIK 0001872863 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,968 Underlying: Common Shares · 16,968 shares Expires 2033-05-31 F2 · derivative.exercise_date: Vests in four nearly equal quarterly installments over one year. Read SEC document |
| January 03, 2023 Filed Jan 3, 2023 21:25 UTC | DiaMedica Therapeutics Inc. DMAC · Entity 5813 | GrantVoting Common Shares, no par value per share | 17,156 | $1.53 | $26,248.68 |
DisclosureSEC source: 0001235802-23-000002 · primary_doc.xml · nonDerivative · entry 1 Semba Charles Pauling · CIK 0001872863 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,156 F1 · shares: These shares are issuable upon vesting of a restricted stock unit award granted under the DiaMedica Therapeutics Inc. 2019 Omnibus Incentive Plan in lieu of cash retainer fees in the aggregate amount of $26,250. The restricted stock unit award will vest in four nearly equal installments on each of March 31, 2023, June 30, 2023, September 30, 2023 and December 31, 2023. F1 · balance_after: These shares are issuable upon vesting of a restricted stock unit award granted under the DiaMedica Therapeutics Inc. 2019 Omnibus Incentive Plan in lieu of cash retainer fees in the aggregate amount of $26,250. The restricted stock unit award will vest in four nearly equal installments on each of March 31, 2023, June 30, 2023, September 30, 2023 and December 31, 2023. Read SEC document |
| June 01, 2022 Filed Jun 2, 2022 20:34 UTC | DiaMedica Therapeutics Inc. DMAC · Entity 5813 | GrantStock Option (right to buy) · Derivative | 13,222 | $0.00 Strike: $2.45 | $0.00 |
DisclosureSEC source: 0001235802-22-000070 · primary_doc.xml · derivative · entry 2 Semba Charles Pauling · CIK 0001872863 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,222 Underlying: Common Shares · 13,222 shares Expires 2032-05-31 F1 · derivative.exercise_date: Vests in four nearly equal quarterly installments over one year. Read SEC document |
| July 15, 2021 Filed Jul 16, 2021 20:21 UTC | DiaMedica Therapeutics Inc. DMAC · Entity 5813 | GrantStock Option (right to buy) · Derivative | 18,786 | $0.00 Strike: $3.64 | $0.00 |
DisclosureSEC source: 0001235802-21-000077 · primary_doc.xml · derivative · entry 2 Semba Charles Pauling · CIK 0001872863 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,786 Underlying: Common Shares · 18,786 shares Expires 2031-07-14 F1 · derivative.exercise_date: Vests in twelve nearly equal quarterly installments over three years. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.